DXCM Maintains by RBC Capital -- Price Target Raised to $105

gurufocus.com · 2026-10-01

On October 18, 2023, RBC Capital maintained an "Outperform" rating for DexCom (DXCM). The price target has been adjusted from $90.00 to $105.00, reflecting a 16

TickrTrends take: RBC Capital's price target raise to $105 reflects analyst confidence in DXCM's fundamentals within the Healthcare sector. Given TickrTrends' current assessment that DXCM is undervalued, this analyst action suggests potential upside if the market reprices the stock toward consensus expectations. Investors focused on valuation metrics should monitor whether the stock moves toward the $105 target, which could narrow the gap between current pricing and the analyst's assessment of intrinsic value.

Read the full story at gurufocus.com →